DE60126737D1 - Modifizierte HPV E6- und E7-Gene und -Proteine als Impfstoff - Google Patents

Modifizierte HPV E6- und E7-Gene und -Proteine als Impfstoff

Info

Publication number
DE60126737D1
DE60126737D1 DE60126737T DE60126737T DE60126737D1 DE 60126737 D1 DE60126737 D1 DE 60126737D1 DE 60126737 T DE60126737 T DE 60126737T DE 60126737 T DE60126737 T DE 60126737T DE 60126737 D1 DE60126737 D1 DE 60126737D1
Authority
DE
Germany
Prior art keywords
dna sequences
protein
vaccine
genes
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60126737T
Other languages
English (en)
Other versions
DE60126737T2 (de
Inventor
Angel Dr Cid-Arregui
Hausen Harald Prof Dr Zur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Application granted granted Critical
Publication of DE60126737D1 publication Critical patent/DE60126737D1/de
Publication of DE60126737T2 publication Critical patent/DE60126737T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
DE2001626737 2001-03-23 2001-03-23 Modifizierte HPV E6- und E7-Gene und -Proteine als Impfstoff Expired - Lifetime DE60126737T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20010107271 EP1243655B1 (de) 2001-03-23 2001-03-23 Modifizierte HPV E6- und E7-Gene und -Proteine als Impfstoff

Publications (2)

Publication Number Publication Date
DE60126737D1 true DE60126737D1 (de) 2007-04-05
DE60126737T2 DE60126737T2 (de) 2007-11-08

Family

ID=8176911

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2001626737 Expired - Lifetime DE60126737T2 (de) 2001-03-23 2001-03-23 Modifizierte HPV E6- und E7-Gene und -Proteine als Impfstoff

Country Status (9)

Country Link
US (3) US7201908B2 (de)
EP (1) EP1243655B1 (de)
JP (1) JP2004531253A (de)
AT (1) ATE354662T1 (de)
AU (1) AU2002312774A1 (de)
DE (1) DE60126737T2 (de)
ES (1) ES2284559T3 (de)
MX (1) MXPA03008559A (de)
WO (1) WO2002081709A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60126737T2 (de) * 2001-03-23 2007-11-08 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Modifizierte HPV E6- und E7-Gene und -Proteine als Impfstoff
US20060099219A1 (en) * 2002-04-24 2006-05-11 Universite Libre De Bruxelles Mutated hpv-16e7 polypeptide, pharmaceutical composition comprising it and its preparation process
CZ297389B6 (cs) * 2003-07-03 2006-11-15 Ústav Molekulární Biologie Rostlin Av Cr Fúzní protein pro vakcinaci proti lidskému papillomaviru a zpusob jeho produkce
JPWO2005049824A1 (ja) * 2003-11-21 2007-11-29 独立行政法人科学技術振興機構 生体構造認識部位を提示する中空ナノ粒子およびその生産方法、並びにその利用
AU2004308964B2 (en) 2003-12-23 2010-09-16 Arbor Vita Corporation Antibodies for oncogenic strains of HPV and methods of their use
EP1699479A1 (de) * 2003-12-24 2006-09-13 Leiden University Medical Center Synthetisches protein als tumorspezifischer impfstoff
KR100755991B1 (ko) 2005-08-11 2007-09-06 신정임 최적화된 유전자 코돈을 가지는 ｅ7 유전자 및 라이소좀타겟팅 시그널 서열을 포함하는 파필로마바이러스 유발질환의 예방 또는 치료용 조성물
WO2007119896A1 (en) * 2006-04-19 2007-10-25 Postech Foundation Compositions comprising hpv polypeptides and immunoenhancement peptides for the treatment and prevention of cervical cancer
KR20090103571A (ko) * 2008-03-28 2009-10-01 바이오코아 주식회사 면역성 펩타이드 및 그 펩타이드를 포함하는 ｈｐｖ 관련질환 예방 또는 치료용 조성물
EP2497494B1 (de) * 2009-11-06 2018-01-24 Chimera Pharma, S. L. U. Imfpstoffe zur behandlung von neoplasien aus viralen birnavirus-kapsiden mit antigenen des humanen papillomavirus
EP2335730A1 (de) * 2009-12-18 2011-06-22 Deutsches Krebsforschungszentrum Fusionspolypeptide und ihre Verwendung zur Vorbeugung und Behandlung von Krebs
PL2604629T3 (pl) 2010-08-13 2018-08-31 Genexine, Inc. Kompozycja do zapobiegania lub leczenia raka szyjki macicy ze wzmacniaczem odporności przeciwko wirusowi brodawczaka ludzkiego
CN103772508B (zh) * 2014-01-15 2017-05-10 深圳泰来生物医药有限公司 免疫增强的人乳头瘤病毒感染及相关疾病的治疗性疫苗
WO2016024255A1 (en) 2014-08-15 2016-02-18 Genexine, Inc. Methods of treating cervical cancer
JP6663438B2 (ja) * 2014-10-24 2020-03-11 エイチピーブイヴァックス, リミテッド ライアビリティー カンパニー.Hpvvax, Llc. 癌および皮膚病変の治療
JP7110108B2 (ja) * 2015-12-09 2022-08-01 ジンガン メディスン（オーストラリア） プロプライアタリー リミティド 治療用免疫調節組成物
CN111019971A (zh) * 2019-12-19 2020-04-17 上海同科生物科技有限公司 在rosa26位点条件性过表达hpv e6基因小鼠模型的构建方法
WO2021215896A1 (en) 2020-04-24 2021-10-28 Genexine, Inc. Method for treating cervical cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882145A (en) * 1986-12-09 1989-11-21 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
DE19819476C1 (de) * 1998-04-30 2000-01-05 Deutsches Krebsforsch Polypeptid mit immunogenen Eigenschaften und veränderten biologischen Funktionen eines Proteins
US7001995B1 (en) * 1999-08-25 2006-02-21 Merck & Co., Inc. Synthetic human papillomavirus genes
WO2001014416A2 (en) * 1999-08-25 2001-03-01 Merck & Co., Inc. Synthetic papillomavirus genes optimized for expression in human cells
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
DE60126737T2 (de) * 2001-03-23 2007-11-08 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Modifizierte HPV E6- und E7-Gene und -Proteine als Impfstoff

Also Published As

Publication number Publication date
ATE354662T1 (de) 2007-03-15
DE60126737T2 (de) 2007-11-08
EP1243655B1 (de) 2007-02-21
US20040171806A1 (en) 2004-09-02
WO2002081709A2 (en) 2002-10-17
US20070196339A1 (en) 2007-08-23
ES2284559T3 (es) 2007-11-16
WO2002081709A3 (en) 2003-03-06
AU2002312774A1 (en) 2002-10-21
US7700114B2 (en) 2010-04-20
MXPA03008559A (es) 2005-03-07
US20070190074A1 (en) 2007-08-16
US7201908B2 (en) 2007-04-10
JP2004531253A (ja) 2004-10-14
EP1243655A1 (de) 2002-09-25

Similar Documents

Publication Publication Date Title
DE60126737D1 (de) Modifizierte HPV E6- und E7-Gene und -Proteine als Impfstoff
HK1150856A1 (en) Il-17 homologous polypeptide and therapeutic uses thereof il-17
BR0113307A (pt) Molécula de proteìna quimérica de núcleo de vìrus de hepatite b recombinante, partìcula imunogênica, vacina ou inóculo, ácido nucleico, molécula de ácido nucleico recombinante, célula hospedeira e método de induzir uma resposta imunológica em um animal hospedeiro inoculado
BRPI0417509A (pt) molécula de proteìna quimérica de núcleo de vìrus da hepatite b (hbc) recombinante, partìculas, vacina ou inóculo, ácido nucleico, molécula de ácido nucleico recombinante, e, célula hospedeira
DK1294876T3 (da) EV-VEGF-nukleinsyrer og -polypeptider samt fremgangsmåder til deres benyttelse
ATE447583T1 (de) Polypeptide und dafür kodierende nukleinsäure
MXPA02006888A (es) Flavivirus recombinantes y metodos para utilizar los mismos.
MX336112B (es) Vacunas e inmunoterapicos que usan il-15 optimizada de codones y metodos para usar los mismos.
DE60033138D1 (de) Polypeptide mit galaktoseoxidaseaktivität und dafür kodierende nukleisäuren
BRPI0409789A (pt) vacina de tuberculose com eficácia aperfeiçoada
DK1108035T3 (da) Behandling af cervixcancer
DE60142922D1 (de) Für antigene polypeptide des hiv type c kodierende nukleinsäuren, entsprechende polypeptide und verwendungen davon
DK1246917T3 (da) Humane Stra6-polypeptider
DE602005015368D1 (de) Immunogenes polypeptid bestehend aus optimierten kryptischen peptiden aus tumorantigenen und seine verwendungen
WO2001090326A3 (en) Novel matrix metalloproteinases
DK1506222T3 (da) Kimæriske, humane papillomavirus16 L1-proteiner omfattende et L2-peptid, viruslignende partikler fremstillet deraf samt en fremgangsmåde til at fremstille partiklerne
ATE310810T1 (de) Polypeptid und dafür kodierendes nukeinsäure
DE60119535D1 (de) Herstellung eines rekombinanten proteins in prokaryotischen wirtszellen durch kodonsoptimisierung
DE60026049D1 (de) POLYPEPTIDE MIT GLUCANOTRANSFERASE AKTIVITÄT UND DAFüR KODIERENDE NUKLEINSÄUREN
WO2002079231A3 (en) Nucleic acids encoding isav polypeptides
DE60038986D1 (de) Ausgeschiedene und Transmembranpolypeptide und dafür kodierende Nukleinsäure
DE60043258D1 (de) Menschliches suppressor von fused
DE69829230D1 (de) Polypeptid und dafür kodieredes Nukleinsäure

Legal Events

Date Code Title Description
8364 No opposition during term of opposition